RT Journal Article
SR Electronic
T1 High seroconversion rate and SARS-CoV-2 Delta neutralization in PLWHIV vaccinated with BNT162b2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21267395
DO 10.1101/2021.12.07.21267395
A1 Pourcher, Valérie
A1 Belin, Lisa
A1 Soulie, Cathia
A1 Rosenzwajg, Michelle
A1 Marot, Stéphane
A1 Lacombe, Karine
A1 Valin, Nadia
A1 Pialoux, Gilles
A1 Calin, Ruxandra
A1 Malet, Isabelle
A1 Zafilaza, Karen
A1 Tubiana, Roland
A1 Valantin, Marc-Antoine
A1 Klatzmann, David
A1 Calvez, Vincent
A1 Simon-Tillaux, Noémie
A1 Marcelin, Anne-Geneviève
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.07.21267395.abstract
AB Objectives To assess the humoral and cellular responses against SARS-CoV-2 Delta variant after BNT162b2 vaccination in PLWHIV.Design Multicenter cohort study of PLWHIV, with a CD4 cell count <500/mm3 and a viral load <50 copies/ml on stable antiretroviral therapy for at least 3 months.Methods Anti-SARS-CoV-2 Receptor Binding Domain IgG antibodies (anti-RBD IgG) were quantified and their neutralization capacity was evaluated using an ELISA (GenScript) and a virus neutralization test (VNT), against historical strain, Beta and Delta variants before vaccination (day 0) and one month after a complete vaccination schedule (M1).Results 97 patients were enrolled in the study: 85 received 2 vaccine doses (11 previous COVID-19 and 1 premature exit). The seroconversion rate in anti-RBD IgG was 97% CI95[90%; 100%] at M1. Median (IQR) anti-RBD IgG titer was 0.97 (0.97-5.3) BAU/ml at D0 and 1219 (602-1929) at M1. Neutralizing antibodies (NAbs) capacity improved between D0 (15% CI95[8%; 23%]) and M1 (94% CI95[87%; 98%]) with the GenScript assay (p<0.0001). At M1, NAbs against historical strain, Beta and Delta variants were present in 82%, 77% and 84% patients respectively. The seroconversion rate and median anti-RBD IgG were 91% and 852 BAU/ml in patients with CD4<250/mm3 (n=13) and 98% and 1270 BAU/ml in patients with CD4>250/mm3 (n=64) (p=0.3994). 73% of patients with CD4<250 had NAbs and 97% of those with CD4>250 (p=0.0130). The NAbs against Beta variant was elicited in 50% in CD4<250 and in 81% in CD4>250 (p=0.0292). No change in CD4+ or CD8+ T cells count was observed while a decrease of CD19+ B cells count was observed (208 ±124 cells/mm3 at D0 vs 188 ±112 cells/mm3 at M1, p<0.01). No notable adverse effects or COVID-19 were reported.Conclusions These results show a high seroconversion rate with a Delta neutralization in PLWHIV patients after a complete BNT162b2 vaccination schedule.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by a grant from Assistance Publique Hopitaux de Paris. Others analyses (not reported here) in the COVIVAC-ID study are supported by Roche laboratory.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study follows the STROBE reporting guidelines (see checklist in supplemental table XX) [17]. The study was registered on ClinicalTrial.gov (NCT04844489). The study was approved by the ethical and scientific committee of Ile de France 8 under the registration number IDRCB 2021-A00469-32. All patients were informed and gave their written consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors